Posts filtered by tags: Merck KGaA[x]


 

Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera

Vertex Pharmaceuticals is best known for its cystic fibrosis franchise. But over the past several years Vertex has been making inroads elsewhere, and a deal it is announcing this morning continues that strategy.Vertex (NASDAQ: VRTX), of Boston, will pay privately held startup Kymera Therapeutics $70 million to form an alliance to develop a group of drugs for “serious specialty diseases.” Vertex won’t say which ones, but beyond cystic fibrosis (CF), where it has three FDA-approved drugs that gen...
Tags: Deals, Startups, Boston, Trends, Vc, Fda, GlaxoSmithKline, Biotech, Pain, Cystic Fibrosis, Life Sciences, CRISPR Therapeutics, Vertex, Merck KGaA, Hepatitis C, Vertex Pharmaceuticals


Africa Roundup: Jumia’s IPO, DHL launches Africa e-Shop, Cathay’s $168M VC fund, ConnectMed acquired

The biggest news in a month of weighty African headlines was Jumia listing on the New York Stock Exchange. After filing SEC IPO docs in March, the Pan-African e-commerce company’s shares began trading on the NYSE April 12, opening at $14.50 under ticker symbol JMIA. Jumia stock rose north of 70 percent on its first day of trading and started this week at $46. With the public listing, Jumia became the first startup from Africa to list on a major global exchange. The IPO raised nearly $200 million...
Tags: Amazon, TC, Spotify, UK, Technology, Ipo, Germany, Nigeria, Africa, Articles, San Francisco, Entrepreneur, Tech, Merck, E-commerce, Ceo


Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.
Tags: Science, United States, Fda, Merck KGaA, Merck KaaA MKGAF, Mavenclad


Merck KGaA goes hostile in $5.9 billion Versum takeover battle

German pharma group Merck KGaA on Tuesday sidestepped the management of takeover target Versum Materials and took its $5.9 billion offer directly to the U.S. chemical company's shareholders.
Tags: Money, businessNews, Merck KGaA


Merck KGaA makes takeover offer for Versum to shareholders

Germany's Merck KGaA on Tuesday said it made a full takeover bid to shareholders of Versum Materials for $48 per share, after a previous deal proposal for the same price was rejected by the U.S. target's management.
Tags: Money, Germany, businessNews, Merck KGaA


Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study

Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.
Tags: Science, Merck KGaA, Pfizer PFE, Pfizer Merck KGaA


Germany's Merck makes $5.9 bln counterbid for Versum

German drugs and lab supplies maker Merck KGaA offered $5.9 billion, including debt, for Versum Materials, in a cash deal that tops an offer from U.S. rival Entegris, as both seek to boost their electrochemicals operations.
Tags: Money, Germany, Merck, businessNews, Merck KGaA, Entegris


Germany's Merck makes $5.9 billion countrebid for Versum

German drugs and lab supplies maker Merck KGaA offered $5.9 billion (4.4 billion pounds), including debt, for Versum Materials, in a cash deal that tops an offer from U.S. rival Entegris, as both seek to boost their electrochemicals operations.
Tags: Money, Germany, Merck, businessNews, Merck KGaA, Entegris


Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate

Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.
Tags: Science, Germany, Merck KGaA, Glaxo GSK, Glaxo Inks Deal With Merck KGaA


GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy. Merck will receive an upfront payment of 300 million euros for the drug - known as M7824, or bintrafusp alfa - and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer, the two companies said in statements on Tuesday. Merck could als...
Tags: Science, Germany, Merck, GlaxoSmithKline, GSK, Merck KGaA


Merck KGaA wins GSK for immunotherapy deal worth up to $4.2 billion

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy. Merck will receive an upfront payment of 300 million euros for the drug known as M7824 and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer, the two companies said in statements on Tuesday. Merck will also be eligible for further paymen...
Tags: Science, Germany, Merck, GlaxoSmithKline, GSK, Merck KGaA


Pfizer/Merck KGaA End Bavencio Ovarian Cancer Phase III Study

Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio. This is the second ovarian cancer study failure in less than two months.
Tags: Science, Merck KGaA, Pfizer PFE, Pfizer Merck KGaA


Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients. The results showed the drug, Bavencio, in combination with, or as a follow-on treatment to, platinum-based chemotherapy could not achieve the primary goal of progression-fee survival in patients. Last year, Bavencio, or avelumab, failed to prolong lives in a separate trial to evaluate the immunotherapy in gastric cancer patients.
Tags: News, Pfizer Inc, Merck KGaA, Merck KGaA Pfizer


INKEF appoints Bulthuis as MD and head of healthcare team

INKEF Capital, a Dutch venture firm, has named Roel Bulthuis as managing director and head of healthcare team. Previously, he worked at M Ventures. PRESS RELEASE AMSTERDAM, November 27, 2018 /PRNewswire/ –INKEF Capital (INKEF), the Dutch venture capital fund focused on technology and healthcare, announces the appointment of Roel Bulthuis as Managing Director and Head of Healthcare Team. He will co-manage the INKEF fund alongside Robert Jan Galema, Head of Technology Team. Roel Bulthuis joins INK...
Tags: Europe, Trends, People, Healthcare, Netherlands, Amsterdam, Msc, ABP, Merck KGaA, Leiden University, Ventures, Bulthuis, M Ventures, Roel, Gent Belgium, Healthcare Technology IT New Media FinTech


Study examines effects of walking exercise training on cognitive function in people with MS

John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, has received a $95,000 sub-award from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.
Tags: Health, Darmstadt Germany, Merck KGaA, MS. John DeLuca, Research and Training at Kessler Foundation


Merck KGaA says might strike partnership deal this year

German drugmaker Merck KGaA might agree partnership deals to jointly develop two of its most promising experimental medicines with a rival as early as this year, but more likely in 2019, its drug research and development chief said on Sunday. "It's possible even as early as the end of the year but that's really a stretch - or sometime in 2019," Luciano Rossetti told Reuters at the annual congress of the European Society for Medical Oncology in Munich on Sunday. Merck has a promising drug pipel...
Tags: Science, Merck, Munich, Reuters, Merck KGaA, European Society for Medical Oncology, Luciano Rossetti


Stada, buyout funds in race for Bristol-Myers’ French business, say sources: Reuters

German generic drugmaker Stada (STAGn.DE) is vying with a group of European buyout funds for control of Bristol-Myers Squibb’s (BMY.N) French over-the-counter drugs business, sources told Reuters. The business, known as Upsa, was put up for sale over the summer. Bidders were asked to submit their offers ahead of a deadline of Oct. 5, the sources said. Investment banks were hired to launch an auction in the second half of the year. The deal is potentially worth about 1 billion euros ($1.15 billio...
Tags: France, Trends, Deutsche Bank, Reckitt Benckiser, Bain Capital, Pai, Reuters, Bristol Myers Squibb, Johnson Johnson, Procter Gamble, CVC Capital Partners, Bristol Myers, Merck KGaA, UPSA, PE Deals, PAI Partners


Gordon named CEO at Gemini Bioproducts

Gemini Bioproducts LLC, a portfolio company of BelHealth Investment Partners LLC, has appointed Dale Gordon as its CEO. Gordon was previously commercial general manager at GE Healthcare Life Sciences, a unit of GE. PRESS RELEASE New York, New York and West Sacramento, CA – September 19, 2018 – Gemini Bioproducts, LLC (“Gemini” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, announced the appointment of D...
Tags: New York, Ge, Trends, Merck, People, Healthcare, Gemini, Board, New York New York, Company, Gordon, Dale, West Sacramento California, Merck KGaA, Bertram, Polan


Bio Roundup: EpiPen Shortage, Bluebird’s Bet, Biotech IPOs & More

It’s back-to-school season and that means it’s time to load up on school supplies. For many students and schools, one crucial item is in high demand but hard to come by: the EpiPen.Some schools stock the epinephrine autoinjectors so they can respond quickly to a student’s allergic reaction to food. Though the autoinjectors are sold by Mylan (NASDAQ: MYL), they’re made by a Pfizer (NYSE: PFE) subsidiary whose manufacturing problems have disrupted shipments. A generic version from Teva Pharmaceut...
Tags: Deals, Startups, Trends, Investing, Merck, IPOs, Mit, Food And Drug Administration, Fda, National, Pfizer, Vaccine, Allergan, Shire, Immunotherapy, Abbvie


Swiss, German drugmakers join U.S. price freeze

Roche, Bayer and Germany's Merck KGaA became the latest drug companies to freeze prices in the United States, amid increased scrutiny by the Trump administration of medicine costs.
Tags: Money, Germany, businessNews, United States, Trump, Merck KGaA, Roche Bayer


Abcam collaborates with Merck to produce anti-PD-L1 antibody clone for global research community

Abcam, a global innovator in life science reagents and tools today announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.
Tags: Health, Merck, Merck KGaA, Abcam


A security guy at JPMorgan spied on employees emails and phone calls using the secretive software tool Palantir

A security expert hired by JPMorgan used software by Palantir to conduct an extensive spying program on the bank's staffers and executives, according to a Bloomberg report. Palantir has raised billions in funding from investors in the private markets, but the company has a reputation for secrecy.  The JPMorgan incident highlights a disturbing aspect of big data technology misuse, but it also sheds light on a major challenge facing Palantir. JPMorgan was once the marquee corporate customer fo...
Tags: Trends, Bloomberg, Peter Thiel, Silicon Valley, Secret Service, Airbus, Palantir, First Data Corp, Jpmorgan, Ivanka Trump, Merck KGaA, Frank Bisignano, Jared Kushner, Bisignano, Palantir JPMorgan, Peter Waldman Lizette Chapman


P&G to buy Merck’s consumer unit for $4.2 billion

Procter & Gamble Co. agreed to buy Merck KGaA’s consumer-health business for $4.2 billion to bolster growth, betting that vitamins and decongestants can hasten its comeback. The deal gives the maker of Crest toothpaste a stable of products with sales growth of 6 percent in the past two years, double the pace of traditional consumer goods such as razors, diapers and tissues. German drugmaker Merck put the the unit up for sale last year as it pumps money into testing new medicines. P&G is under pr...
Tags: Deals, Business, Germany, Israel, Merck, Sport, Frankfurt, Soccer, Novartis, Pfizer, Reckitt, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Procter Gamble Co, Mylan NV, Amazon com Inc


P&G to buy German Merck's consumer health unit for $4.2 billion

(Reuters) - Procter & Gamble Co will acquire the consumer health business of Merck KGaA for about 3.4 billion euros ($4.2 billion), giving it vitamin brands such as Seven Seas and greater exposure to Latin American and Asian markets.
Tags: Money, Merck, businessNews, Merck KGaA, Reuters Procter Gamble Co


P&G to Buy German Merck's Consumer Health Business for About $4.21 Billion

(Reuters) - Procter & Gamble Co agreed to acquire the consumer health business of German pharmaceuticals company Merck KGaA for about 3.4...
Tags: Merck KGaA, Reuters Procter Gamble Co, Merck s Consumer Health Business for About


Mylan Seeks Deal for German Merck's Consumer Products Unit: Sources

FRANKFURT/NEW YORK (Reuters) - Generic drug maker Mylan is in advanced discussions to acquire Merck KGaA's consumer health business after...
Tags: Merck, Frankfurt, Mylan, Merck KGaA, NEW YORK Reuters Generic


Lundbeck to acquire VC-backed Prexton

Lundbeck has agreed to acquire Prexton Therapeutics for 100 million euros and will later pay up to 805 million euros in development and sales milestones. Based in The Netherlands and in Switzerland, Prexton is a biopharmaceutical company. Prexton’s investors include Forbion, Seroba Life Sciences, Sunstone Capital and Ysios Capital. PRESS RELEASE Valby, Denmark, Oss, The Netherlands, 16 March 2018 – H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a defi...
Tags: Trends, Italy, Healthcare, Netherlands, M&a, The Netherlands, Lid, Geneva Switzerland, Merck KGaA, Lundbeck, Prexton, Prexton Therapeutics, Switzerland Prexton, Forbion Seroba Life Sciences Sunstone Capital, Ysios Capital PRESS RELEASE Valby Denmark Oss, Prexton Therapeutics BV Prexton


CLEARink's products are expected to come to market in 2019

M Ventures, the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany and CLEARink Displays announced today that M Ventures has made an investment in CLEARink’s C Round. CLEARink started its C Round of investment mid 2017 with a lead investment and co-investments by China based strategic investors involved in the electronic display industry. Following this, additional investments were received from strategic investors in the U.S. and Taiwan. This latest investment from M...
Tags: Books, News, China, Taiwan, Shenzhen China, Darmstadt Germany, Merck KGaA, Ventures, CLEARink Displays, Frank Christiaens, Owen Lozman


Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More

The 2018 Winter Olympics will end soon, and we did not skate through these games without a performance-enhancing drug allegation rearing its ugly head. This time, the drug in question was meldonium (Mildronate), a product widely available over the counter in Russia and some Eastern European countries. Though Latvian pharmaceutical company Grindeks markets meldonium for heart conditions, the drug also reportedly boosts stamina and endurance. Meldonium is not approved by the FDA for any use...
Tags: Deals, Startups, Russia, Cancer, Trends, Investing, Merck, Food And Drug Administration, Affordable Care Act, Astrazeneca, Fda, National, Parkinson's Disease, Immunotherapy, Abbvie, Biotech


Merck's consumer health sale at risk as Nestle bows out - sources

LONDON/FRANKFURT (Reuters) - The sale of Merck KGaA's consumer health unit has been thrown off track after Nestle has pulled out, leaving the race to buy the maker of Seven Seas vitamins without its main contender, sources familiar with the matter told Reuters.
Tags: London, Money, Merck, businessNews, Nestle, Merck KGaA, FRANKFURT Reuters